Business Wire

FONDATION-IPSEN

19.11.2016 16:21:30 CET | Business Wire | Press release

Share
The 21st Longevity Prize of the Fondation Ipsen will be awarded to Kaare Christensen

The Fondation IPSEN Longevity Prize will be given this year at the GSA meeting (Gerontological Society of America), in New Orleans on November 19th, 2016. The international jury chaired by Professor Thomas Kirkwood (Newcastle University, UK and Copenhagen University, Denmark), have unanimously decided to award the prize to Kaare Christensen for his pioneering work on the importance of genes and environment in aging and longevity.

Kaare Christensen, MD, PhD, DRMSC, is Professor of Epidemiology at the University of Southern Denmark and Senior Research Scientist at the Terry Sanford Institute, Duke University, North Carolina, USA. Dr. Christensen is the Director of the Danish Twin Registry and the Danish Aging Research Center. He has conducted a long series of studies among twins and the oldest-old in order to shed light on the importance of genes and environment in aging and longevity. Furthermore, he has a longstanding interest in the relation between early life events and later life health outcome.

Abstract of his lecture: “Is Mortality written on the face? Or Elsewhere?”

Predicting length of life is of interest to individuals, medical doctors, demographers and researchers on aging. While most people would probably be uncomfortable with an exact prediction at an individual level (if that were possible), the identification of factors associated with health and survival can potentially provide the basis for decision making, interventions and public health initiatives. A series of “the usual suspects” is known to be associated with health and survival, e.g. birth cohort, gender, smoking and other life style factors, genetics, early life and socioeconomic factors. Over the last decades, this list has been extended with biomarkers of aging that include performance measures and molecular markers such as leukocyte telomere length and DNA methylation age. We have used nationwide cohort studies of twins, oldest-old individuals and long-lived families in Denmark to understand variance in health and survival and to identify clinically useful biomarkers of aging. Perhaps surprisingly, we have found that among the elderly, simple, low-tech biomarkers, including perceived age based on photos, are among the most powerful indicators of aging.

The Longevity Prize

Created in 1996, this Prize of the Fondation Ipsen has been awarded every year to renowned specialists in Longevity:

Caleb E. Finch (University of Southern California, Los Angeles, USA), Vaïno Kannisto (Odense University, Denmark) , Roy L. Walford (formerly University of California Los Angeles, USA), John E. Morley (St. Louis University, USA), Paul B. and Margret M. Baltes (formerly Free University of Berlin, Germany), Justin D. Congdon (University of Georgia, Aiken, USA), George M. Martin (University of Washington, Seattle, USA), James W. Vaupel (Max-Planck Institute for Demographic Research, Rostock, Germany), Linda Partridge (University College London, UK), Sir Michael Marmot (University College London, UK), Cynthia Kenyon (University of California, San Francisco, USA), David J.P. Barker (University of Southampton, UK), Gerald McClearn (Pennsylvania State University, University Park, USA), Jacques Vallin (French National Institute of Demography, Paris, France), Judith Campisi (Buck Institute for Age Research, Novato, USA), Thomas Kirkwood (Newcastle University, Newcastle upon Tyne, UK), Linda Fried (Columbia University, New York, USA), Gary Ruvkun (Harvard Medical School - CCIB, Boston, US), Luigi Ferrucci (National Institute on Aging, NIH, Baltimore, USA) and Steven N. Austad (University of Alabama at Birmingham, USA).

Members of the jury

Thomas Kirkwood, President (Newcastle University, UK Copenhagen University, Denmark), Judith Campisi (Buck Institute for Research on Aging, Novato, USA), Eileen Crimmins (University of Southern California, Los Angeles, USA), Caleb Finch (University of Southern California, Los Angeles, USA), Bernard Jeune* (University of Southern Denmark, Odense, Denmark), George Martin* (University of Washington, Seattle, USA), Yasuyuki Gondo (Osaka University, Japan), Jean-Marie Robine (INSERM, Démographie et Santé, Montpellier, France), Bruno Vellas (University of Toulouse, France), Marja Jylhä (University of Tampere, Finland), Steven N. Austad (University of Alabama at Birmingham, USA), Luigi Ferrucci (National Institute on Aging, Baltimore, USA) and a Fondation IPSEN representative.

(* Former Jury Members).

The Fondation IPSEN

Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche, dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the science journals Cell and Science. The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.

www.fondation-ipsen.org

Contact:

Image Sept
Isabelle de Segonzac, +33 (0)1 53 70 74 70
isegonzac@image7.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Braun Launches the Next Generation of Electric Shaver With Braun NEVO Introducing a New Dawn of Smooth Touch2.7.2026 08:00:00 CEST | Press release

With over 100 years of exceptional German craftsmanship, Braun introduces Braun NEVO, an electric shaver redefining what a close shave and smooth skin mean. Every element has been reimagined: the sleek unibody stainless steel handle, the revolutionary AeroTouch™ Technology and advanced personalized display deliver a perfectly close shave without sacrificing comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701842080/en/ Braun NEVO Shaver Oliver Grabes, Braun Head of Design, said: “At Braun, we set out to reimagine the shaving experience which led to the development of AeroTouch™ Shaving Technology, a cutting system engineered for ultra-low friction on the skin and high efficiency. This makes Braun NEVO our best shaver* setting a new standard for smooth skin.” Introducing the revolutionary world’s first AeroTouch™ Technology, featuring 250 diamond-sharp cutting edges and an exclusive Ultra gliding foil for a smooth g

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member2.7.2026 08:00:00 CEST | Press release

Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE, who will remain an active board member. Eric brings extensive experience in healthcare innovation and value creation, having notably led BIOCORP through its development and acquisition by Novo Nordisk. Brenus also appoints Camilla SYLVEST, as a second independent director, following the earlier addition of Diala EZZEDDINE a seasoned US-based biotech executive and entrepreneur. Camilla SYLVEST is an experienced pharmaceutical executive and global business leader, having spent nearly three decades at Novo Nordisk A/S, where she most recently served as Executive Vice President for Global Commercial Strategy, Corporate Communication and Sustainability. She currently serves on the Boards of Argenx SE, Getinge AB, and Zealand Pharma A/S, and has previously served on the Board of Danish Crown A/S and as

Access Advance and Alibaba Announce Alibaba's Expanded Participation in the VDP Pool2.7.2026 02:00:00 CEST | Press release

Access Advance LLC and Alibaba Group today announced that Alibaba has joined the Access Advance Video Distribution Patent Pool (VDP Pool) as a Licensee, securing a license to the pool's comprehensive coverage of HEVC, VVC, VP9, and AV1 codec technologies. The announcement marks a milestone in a multi-year collaboration between the two companies that spans the VVC Advance Patent Pool, where Alibaba participates as both a Licensor and Licensee, and the VDP Pool, where Alibaba joined as a Licensor in 2025. Alibaba's subsidiary Youku, one of China's leading streaming platforms, also joined the VDP Pool as a Licensee in 2025. Alibaba operates one of the world's most diverse video ecosystems, spanning a wide range of video-based services across e-commerce, entertainment, and digital media. As video has become central to how consumers shop, communicate, and access entertainment, the breadth of Alibaba's video operations reflects the kind of business model complexity the VDP Pool was designed

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia2.7.2026 01:58:00 CEST | Press release

- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT. “Just as we redefined what is possible in cystic fibrosis, our ambition is to transform

Andersen Global styrker sine kompetencer inden for skat og global mobilitet i Tyskland2.7.2026 00:13:00 CEST | Pressemeddelelse

Andersen Global styrker sin tilstedeværelse gennem en samarbejdsaftale med Lohr and Company (L+C), der er en erfaren skatterådgivningsvirksomhed, der leverer praktiske og fleksible løsninger inden for skattecompliance, internationale skatteforhold, global mobilitet og transfer pricing. L+C har hovedkontor i Tyskland og er også til stede i Østrig og rådgiver store multinationale selskaber, familieejede virksomheder, familievirksomheder, fonde og formuende privatpersoner. L+C blev grundlagt i 2001 og har specialiseret sig i global mobilitet, opkøb og fusioner, international skattelovgivning, rapportering mellem lande og transfer pricing, herunder rapportering i henhold til Pillar 2. Derudover bistår L+C sine kunder med trusts og fonde, skattecompliance, løn- og regnskabsadministration samt privatøkonomisk rådgivning. "Samarbejdet med Andersen Global er et vigtigt skridt i udvidelsen af vores internationale kompetencer og styrker den værdi, vi skaber for kunder, der navigerer i stadig mer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye